RT Journal Article
SR Electronic
T1 Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20180851
DO 10.1101/2020.08.24.20180851
A1 O’Driscoll, Megan
A1 Santos, Gabriel Ribeiro Dos
A1 Wang, Lin
A1 Cummings, Derek A.T.
A1 Azman, Andrew S.
A1 Paireau, Juliette
A1 Fontanet, Arnaud
A1 Cauchemez, Simon
A1 Salje, Henrik
YR 2020
UL http://medrxiv.org/content/early/2020/08/26/2020.08.24.20180851.abstract
AB The number of COVID-19 deaths is often used as a key indicator of SARS-CoV-2 epidemic size. However, heterogeneous burdens in nursing homes and variable reporting of deaths in elderly individuals can hamper comparisons of deaths and the number of infections associated with them across countries. Using age-specific death data from 45 countries, we find that relative differences in the number of deaths by age amongst individuals aged <65 years old are highly consistent across locations. Combining these data with data from 15 seroprevalence surveys we demonstrate how age-specific infection fatality ratios (IFRs) can be used to reconstruct infected population proportions. We find notable heterogeneity in overall IFR estimates as suggested by individual serological studies and observe that for most European countries the reported number of deaths amongst ≥65s are significantly greater than expected, consistent with high infection attack rates experienced by nursing home populations in Europe. Age-specific COVID-19 death data in younger individuals can provide a robust indicator of population immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the University of Cambridge COVID-19 Rapid Response Grant, the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sante Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union's Horizon 2020 research and innovation program under grants 101003589 (RECOVER) and 874735 (VEO), AXA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data necessary to reproduce this analysis are available at 491 https://github.com/meganodris/International-COVID-IFR. https://github.com/meganodris/International-COVID-IFR